Tonight's the big night for cancer drug watchers. ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
Peter Loftus at Dow Jones lists Pfizer ($PFE), GlaxoSmithKline ($GSK) and Johnson & Johnson ($JNJ) among the big names that will be featured tonight. But Bristol-Myers Squibb ($BMY) and Roche (T-DM1) plan to hold back on the headlines until the confab in Chicago gets under way.
For GSK, dabrafenib and trametinib are slated for top billing. Together, the two therapies could earn more than $700 million a year, Cowen reports. Pfizer, meanwhile, will be looking to make a case to expand the approval for Xalkori while J&J will make a case for Zytiga.
As Loftus notes in his report, one of the big themes this year will be the continued focus on personalized medicine, as investigators look for better results from cancer therapies targeted to specific patient populations.
- here's the story from Dow Jones
Special Report: Top 10 Late-Stage Cancer Drugs ? 2012
Related Articles:
Cancer drug developers angling for center stage at ASCO
Support seen for U.S. plan to speed nods for 'breakthrough' drugs
J&J's Zytiga's pain relief, ease of use beat Provenge
Oncologists lament growing drug shortages
nicole richie esperanza spalding lyme disease symptoms cardinals jessica sanchez robert kennedy san diego weather
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.